新一代非苯二酚安眠藥造成急性肝炎住院之危險因子分析：以台灣健保資料庫連結研究

Risk of hospitalization for acute hepatitis in patients treated with non-benzodiazepine hypnosedatives: case-crossover study from the National Health Insurance in Taiwan

詹毓哲(Yu-Tse Tsan)

指導教授 ： 陳保中

國立臺灣大學/公共衛生學院/職業醫學與工業衛生研究所/碩士(2007年)

https://doi.org/10.6342/NTU.2007.00143

摘要

簡介：隨著安眠藥於全世界廣泛使用，其安全性備受重視，除常見中樞神經副作用外，安眠藥引起的肝毒性亦不容忽視。大部分安眠藥需經過肝臟代謝，而安眠藥引起之肝毒性均為病例報告，沒有大型流行病學研究。因此，我們研究目的試圖驗證苯二酚和新一代安眠藥與急性肝炎住院間的關聯。
方法：從1997年至2004年的健保資料庫連結，依研究定義找出個案與前後各兩組對照組，然後去分析不同暴露時段，同時將個案分成乙型、丙型、酒精、非病毒非酒精性肝炎等組別，接著利用個案交叉研究方法算出因急性肝炎住院的勝算比。
結果：45,626個案因急性肝炎住院，連結門診檔分析後發現於急性肝炎住院前一週接受Zolpidem處方之勝算比為2.4 (95％信賴區間 1.9, 3.0)。而Zopiclone位第一週暴露時間，其勝算比為1.5 (95％信賴區間 1.0, 2.4)。對於傳統苯二酚，亦以住院前一週勝算比最明顯。此外，根據調整過之勝算比趨勢，另一高峰呈現於前三至六週。
討論：Zolpidem、zopiclone還有傳統苯二酚安眠藥處方時，會增加急性肝炎住院的風險應特別注意，且常見反應為非特異性與非線性劑量。臨床醫師使用這類潛在風險之安眠藥時，需定期監測肝功能。

關鍵字

藥物流行病學 ； 健保資料庫 ； 苯二酚 ； 安眠藥

並列摘要

Introduction: With extensive use of hypnosedatives worldwide, in addition to the most commonly reported side effects of sedation, liver injury induced by benzodiazepines (BZDs) has been reported and should be monitored. BZDs, zolpidem and zopiclone all undergo hepatic metabolism. Hepatoxicity has been suspected so the aim of this study was to determine the association between the use of BZDs, zolpidem, zopiclone and the risk of hospitalization related to acute hepatitis.
Methods: The study cohort dataset was obtained from the National Health Insurance (NHI) research database in Taiwan from 1997-2004. We separated the groups of patients diagnosed before selected admission of outpatient visits or hospitalization as viral hepatitis B, C, non-viral, non-alcoholic hepatitis, alcoholic hepatitis. Since there were so many determinants, or potential confounders for acute hepatitis, we applied case-crossover design as a means of controlling factors within subjects.
Results: 45,626 cases of hospitalization relating to acute hepatitis were obtained. The odds ratio for the first week was the largest and most significant for these medicines. Conditional logistic regression analysis showed a significant adjusted odds ratio of 2.4 (95% confidence interval 1.9, 3.0) for zolpidem during the 7-day risk period. The adjusted odds ratio of zopiclone was 1.5 (95% confidence interval 1.0, 2.4) during the 7-day exposure period. In BZDs, the results were similar to the previous two drugs. In addition, based on the trend of the adjusted odds ratios, another peak was found during the 3 to 6-week period.
Discussion: There is an increased risk of hospitalization for acute hepatitis in patients treated with zolpidem, zopiclone and benzodiazepines, and most severe drug induced liver injuries can be idiosyncratic and dose-independent. Thus, physicians and clinical pharmacists should take such potential into consideration and monitor the liver function of patients taking hypnosedatives suspected to be hepatotoxic.

並列關鍵字

pharmacoepidemialogy, National Health Insurance File and NHI Major Disease File ； benzodiazepine ； zolpidem ； zopiclone ； hepatotoxicity ； hypnosedative.

參考文獻

28. Department of Health. Health and national health insurance annual statistics in Taiwan. Available at: http://www.doh.gov.tw/statistic/index.htm accessed 27 July 2007.

1. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985;42(3):225-32.

2. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003;26(4):261-82.

3. Silber MH. Clinical practice. Chronic insomnia. N Engl J Med 2005;353(8):803-10.

4. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Bmj 2005;331(7526):1169.